Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.2146 +0.0046 (+2.19%) 04/04/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.2015 -0.0131 (-6.10%) 19:32 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.1905
Day High
0.2146
Open 0.2012
Previous Close 0.2100 0.2100
Volume 2,400,500 2,400,500
Avg Vol 1,801,765 1,801,765
Stochastic %K 13.42% 13.42%
Weighted Alpha -89.05 -89.05
5-Day Change -0.0354 (-14.16%) -0.0354 (-14.16%)
52-Week Range 0.1905 - 1.4500 0.1905 - 1.4500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,469
  • Shares Outstanding, K 173,662
  • Annual Sales, $ 2,560 K
  • Annual Income, $ -37,450 K
  • EBIT $ -36 M
  • EBITDA $ -36 M
  • 60-Month Beta 0.58
  • Price/Sales 15.48
  • Price/Cash Flow N/A
  • Price/Book 1.76
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.71
  • Most Recent Earnings $-0.20 on 03/25/25
  • Next Earnings Date 05/06/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 395.57% ( -28.96%)
  • Historical Volatility 93.85%
  • IV Percentile 98%
  • IV Rank 71.15%
  • IV High 550.21% on 03/31/25
  • IV Low 14.18% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 75
  • Volume Avg (30-Day) 271
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 28,648
  • Open Int (30-Day) 29,810

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 4
  • High Estimate -0.02
  • Low Estimate -0.19
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +46.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1905 +12.65%
on 04/04/25
Period Open: 0.3658
0.3823 -43.87%
on 03/07/25
-0.1512 (-41.33%)
since 03/04/25
3-Month
0.1905 +12.65%
on 04/04/25
Period Open: 0.7421
0.8142 -73.64%
on 01/30/25
-0.5275 (-71.08%)
since 01/03/25
52-Week
0.1905 +12.65%
on 04/04/25
Period Open: 1.4700
1.4500 -85.20%
on 04/05/24
-1.2554 (-85.40%)
since 04/04/24

Most Recent Stories

More News
X4 Pharmaceuticals: Q4 Earnings Snapshot

X4 Pharmaceuticals: Q4 Earnings Snapshot

XFOR : 0.2146 (+2.19%)
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

XFOR : 0.2146 (+2.19%)
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

XFOR : 0.2146 (+2.19%)
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

XFOR : 0.2146 (+2.19%)
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

XFOR : 0.2146 (+2.19%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFOR : 0.2146 (+2.19%)
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

XFOR : 0.2146 (+2.19%)
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

XFOR : 0.2146 (+2.19%)
X4 Pharmaceuticals to Present Pivotal Phase 3 Trial Data for Mavorixafor at ASH Annual Meeting 2024

X4 Pharmaceuticals announces presentations at the ASH Annual Meeting on mavorixafor for chronic neutropenia treatment.Quiver AI SummaryX4 Pharmaceuticals announced its participation in the 66th American...

XFOR : 0.2146 (+2.19%)
X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

XFOR : 0.2146 (+2.19%)

Business Summary

X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 0.2467
2nd Resistance Point 0.2307
1st Resistance Point 0.2226
Last Price 0.2146
1st Support Level 0.1985
2nd Support Level 0.1825
3rd Support Level 0.1744

See More

52-Week High 1.4500
Fibonacci 61.8% 0.9689
Fibonacci 50% 0.8203
Fibonacci 38.2% 0.6716
Last Price 0.2146
52-Week Low 0.1905

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades